Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will conduct a group randomized trial to test the effects of a hula-based intervention in improving vascular risk factors for ADRD and cognitive complaints and function over 12 months.
This study will conduct a pragmatic group-randomized trial (GRT) with NHPIs aged 50-75 years with at least 1 of 4 modifiable vascular risk factors for ADRD (hypertension, hyperglycemia, obesity, or dyslipidemia) and either SCI or MCI using a wait-list control design to test the effects of the hula-based intervention. The primary outcomes will be vascular risk factors for ADRD and subjective cognitive complaints. Secondary outcomes will include measures of cognitive performance, physical function, and mental health.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | The intervention group will immediately receive the Ola Mau i ka Hula intervention after randomization for 12 months. The intervention program is 8 months with a 4 month self-monitoring period. |
|
| Wait-list control group | No Intervention | After baseline data collection, participants randomized to the wait-list control arm will not receive the Ola Mau i ka Hula Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not be offered the intervention until after the intervention arm is completed and their 12-month follow-up data collection is completed. They will only receive the educational component of the intervention from us during this 12-month period but they will be instructed to continue with their routine medical care as usual. Wait-list control group will be offered the opportunity to receive intervention at the conclusion of 12 month assessment period, regardless of whether they were retained for the full 12 months of data collection. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ola Mau i ka Hula | Behavioral | The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons. These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network. For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in participants' systolic blood pressure at each time frame from baseline | Vascular risk factor assessed using Omron©HEM-907XL | 3 months, 8 months, 12 months |
| Change in participants' Hemoglobin A1c at each time frame from baseline | Vascular risk factor assessed using Alere Cholestech LDX® System | 12 months |
| Change in participants' total cholesterol at each time frame from baseline | Vascular risk factor assessed using Alere Cholestech LDX® System | 3 months, 8 months, 12 months |
| Change in participants' body mass index at each time frame from baseline | Vascular risk factor assessed using Tanita BWB800AS scale | 3 months, 8 months, 12 months |
| Change in participants' Cognitive Change Index score at each time frame from baseline | Cognitive function assessed using Cognitive Change Index assessment | 3 months, 8 months, 12 months |
| Change in participants' Number Symbol Coding Test score at each time frame from baseline | Cognitive function assessed using Number Symbol Coding Test | 3 months, 8 months, 12 months |
| Change in participants' overall Cognivue score at each time frame from baseline | Cognitive function assessed using Cognivue device |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Janice K Worthington, MPH | Contact | 8086921023 | ikekupuna@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Joseph K Kaholokula, PhD | University of Hawaii | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kula No Na Po'e | Recruiting | Honolulu | Hawaii | 96813 | United States |
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D000544 | Alzheimer Disease |
| D015140 | Dementia, Vascular |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D003704 | Dementia |
Not provided
Not provided
The study uses a wait list control design, where the wait-list control group is offered the intervention at the completion of the intervention group's 12-month intervention and assessment period.
Not provided
Not provided
Not provided
Not provided
|
|
| 3 months, 8 months, 12 months |
| Change in participants' overall Quick Dementia Rating System score at each time frame from baseline | Cognitive function assessed using Quick Dementia Rating System assessment | 3 months, 8 months, 12 months |
| Kokua Kalihi Valley | Recruiting | Honolulu | Hawaii | 96819 | United States |
|
| Hui No Ke Ola Pono | Recruiting | Wailuku | Hawaii | 96793 | United States |
|
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D002561 | Cerebrovascular Disorders |
| D002537 | Intracranial Arteriosclerosis |
| D020765 | Intracranial Arterial Diseases |
| D056784 | Leukoencephalopathies |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |